Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction

Circulation

Volumn 96, Issue 1, 1997, Pages 192-201

  Yusuf, Salim ^a  

^a HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

Myocardial infarction; Patients; Trials

Indexed keywords

POLOXAMER; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ARTICLE; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HEART INFARCTION SIZE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

CORONARY ANGIOGRAPHY; CREATININE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLOXALENE; SURFACE-ACTIVE AGENTS; SURVIVAL RATE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME; VASCULAR PATENCY; VENTRICULAR FUNCTION, LEFT;

EID: 0030789176     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Yusuf S, Sleight P, Held P, McMahon S. Routine medical management of acute myocardial infarction: lessons from overviews of recent randomized controlled trials. Circulation. 1990;82(suppl II):II-117-II-134.
2. ISIS-4. A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction: ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345:669-685.
3. Carter C, Fisher TC, Hamai H, Johnson CS, Mussulman HE, Nah GB, Stuart J. Haemorheological effects of a nonionic copolymer surfactant (poloxamer 188). Clin Hemorheol. 1992;12:109-120.
4. Grover FL, Kahn RS, Heron MW, Paton BC. A nonionic surfactant and blood viscosity: experimental observations. Arch Surg. 1973;106:307-310.
5. Hunter RL, Bennett B, Check IJ. The effect of poloxamer 188 on the rate of in vitro thrombolysis mediated by t-PA and streptokinase. Fibrinolysis. 1990;4:117-123.
6. Carr ME Jr, Powers PL, Jones MR. Effects of poloxamer 188 on the assembly, structure, and dissolution of fibrin clots. Thromb Haemost. 1991;66:565-568.
7. Robinson KA, Hunter RL, Stack JE, Hearn JA, Apkarian RP, Roubin GS. Inhibition of coronary arterial thrombosis in swine by infusion of poloxamer 188. J Invas Cardiol. 1990;2:9-20.
8. Schaer GL, Hursey TL, Abrahams SL, Buddemeier K, Ennis B, Rodriguez ER, Hubbell JP, Moy J, Parrillo JE. Reduction in reperfusion-induced myocardial necrosis in dogs by RheothRx injection (poloxamer 188, N.F.), a hemorheological agent that alters neutrophil function. Circulation. 1994;90:2964-2975.
9. Schaer GL, Spaccavento LJ, Browne KF, Krueger KA, Krichbaum D, Phelan JM, Fletcher WO, Grines CL, Edwards S, Jolly MK, Gibbons RJ. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction: results of a randomized, double-blind, placebo-controlled trial. Circulation. 1996;94:298-307.
10. Grines CL, O'Keefe JH, DeWood MA, Kalbfleisch JM, Magorien R, Gibbons RJ, Mason D, Krueger K. A prospective, randomized, placebo-controlled trial of RheothRx (poloxamer 188, N.F.) to limit infarct size in humans. Circulation. 1993;88(suppl I):I-292. Abstract.
11. Wall RC, Califf RM, Blankenship J, Talley D, Tannenbaum M, Schwaiger M, Gacioch G, Cohen M, Sanz M, Leimberger J, Topol EJ. Intravenous fluosol in the treatment of acute myocardial infarction: results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. Circulation. 1994;90:114-120.
12. Weaver WD. Randomized, placebo controlled trial of RheothRx (poloxamer 188) injection in patients with suspected acute myocardial infarction (AMI). Circulation. 1995;92(suppl I):I-24. Abstract.
13. Gore JM, Sloan M, Price TR, Randall AMY, Bovil E, Collen D, Forman S, Knatterud GL, Sopko G, Terrin ML, and the TIMI Investigators. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Circulation. 1991;83:448-459.
14. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation. 1994;90:1624-1630.
15. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631-1637.
16. Neuhaus KL, von Essen R, Tebbe U, Jessel A, Heinrichs H, Maurer W, Doring W, Harmjanz D, Kotter V, Kaihammer E, Simon H, Horacek T. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circulation. 1994;90:1638-1642.